• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23156 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Austrian Institute for Health Technology Assessment (AIHTA) Role of public contributions to the development of health innovations and its integration in value assessment and pricing/reimbursement decisions
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Liposuction for the removal of subcutaneous (large) lipomas]
2024     Scottish Health Technologies Group (SHTG) Green theatres
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
2024     Agency for Care Effectiveness (ACE) Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
2024     Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2024     Agency for Care Effectiveness (ACE) Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2024     Agency for Care Effectiveness (ACE) Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
2024     NIHR Health Services and Delivery Research programme ‘Why are we stuck in hospital?’ Barriers to people with learning disabilities/autistic people leaving ‘long-stay’ hospital: a mixed methods study
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     NIHR Health Technology Assessment programme Strategies used for childhood chronic functional constipation: the SUCCESS evidence synthesis
2024     NIHR Health Technology Assessment programme Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
2024     NIHR Health Technology Assessment programme Development and evaluation of a de-escalation training intervention in adult acute and forensic units: the EDITION systematic review and feasibility trial
2024     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of an adapted intervention for preschoolers with moderate to severe intellectual disabilities displaying behaviours that challenge: the EPICC-ID RCT
2024     NIHR Health Technology Assessment programme Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of chronic obstructive pulmonary disease in Quebec from 2016 to 2022 - healthcare Indicator results]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “type 1 diabetes”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fracture sonography in children with suspected fracture of a long tubular bone of the upper extremities]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, neoadjuvant) – Addendum to Project A23-74]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency, adults) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     NIHR Health Services and Delivery Research programme Conceptual framework on barriers and facilitators to implementing perinatal mental health care and treatment for women: the MATRIx evidence synthesis
2024     NIHR Health Services and Delivery Research programme Factors within the clinical encounter that impact upon risk assessment within child and adolescent mental health services: a rapid realist synthesis
2024     NIHR Public Health Research (PHR) programme Support needs of survivors of violence against women in urban India: a prospective analysis of client records
2024     Health Information and Quality Authority (HIQA) Advances in the development of clinical practice guidance - scoping review
2024     Health Information and Quality Authority (HIQA) Enhanced inactivated influenza vaccines for over 65s: protocol for a health technology assessment
2024     Health Information and Quality Authority (HIQA) Herpes zoster (shingles) vaccination: protocol for a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     Health Technology Wales (HTW) Intensive family preservation programmes for families in crisis
2024     Health Technology Wales (HTW) Video feedback interventions to improve communication within family relationships and support children at risk
2024     Health Technology Wales (HTW) Low energy contact x-ray brachytherapy (CXB) for the treatment of early stage rectal cancer
2024     Health Technology Wales (HTW) Digital tools for the monitoring and management of wounds
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Swiss Federal Office of Public Health (FOPH) Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2024     Swiss Federal Office of Public Health (FOPH) CAR-T-cell therapies
2024     Swiss Federal Office of Public Health (FOPH) Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2024     Belgian Health Care Knowledge Centre (KCE) Diagnostic Immunohistochemistry and electron microscopy testing in Belgium
2024     Belgian Health Care Knowledge Centre (KCE) Lung cancer screening in a high-risk population
2024     Belgian Health Care Knowledge Centre (KCE) The use of endothelial cell counting in the preoperative evaluation of cataract surgery (Study 2023-12)
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal sympathetic denervation for the management of resistant hypertension]
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA)
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic and clinical utility of impulse oscillometry for use in patients with difficulty performing spirometry]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Nivolumab plus ipilimumab in pleural mesothelioma]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [FONAKIDs® multimodal approach in congenital or acquired apraxia of speech]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Use of biomaterials in tympanoplasty for tympanic membrane repair]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation for dystonia refractory to medical treatment]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multiplex PCR for moderate to severe acute lower respiratory tract infections]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Medial pivot prosthesis in primary total knee arthroplasty]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [CROS and BICROS hearing aids in unilateral and asymmetric bilateral hearing loss]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Cannabidiol in epilepsy. National versus international products comparison]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Levonorgestrel-releasing intrauterine device as contraceptive method in women of childbearing age]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation of parathyroid glands]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in triple-negative breast cancer]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in amyotrophic lateral sclerosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multigene panel testing for tumors of known origin]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Mortality review 2023 update
2023     HTA South [Focused ultrasound treatment for tremor]
2023     National Institute for Health and Care Excellence (NICE) Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. NICE interventional procedures guidance 747
2023     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. NICE interventional procedures guidance 748
2023     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. NICE interventional procedures guidance 749
2023     National Institute for Health and Care Excellence (NICE) Trabeculectomy with a biodegradable collagen matrix implant for glaucoma. NICE interventional procedures guidance 750
2023     National Institute for Health and Care Excellence (NICE) Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE interventional procedures guidance 752
2023     National Institute for Health and Care Excellence (NICE) Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transluminal renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 754